Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer

Jennifer Taylor Veneris, Lei Huang, Jane E. Churpek, Suzanne D. Conzen, Gini F. Fleming

Research output: Contribution to journalArticle

Abstract

Objective High glucocorticoid receptor (GR) protein expression is associated with decreased progression-free survival in ovarian cancer patients and decreased sensitivity to chemotherapy in preclinical models. Prior studies suggest wild type BRCA1 promotes GR activation. The objective of this study was to characterize the relationship of tumor GR gene expression to outcome in ovarian cancer, and to evaluate the relationship of GR expression with BRCA status. Methods Whole exome and whole genome sequencing, gene expression, and clinical data were obtained for high-grade serous ovarian cancers in The Cancer Genome Atlas. Cases with pathogenic somatic or germline BRCA1 or BRCA2 mutations were identified and classified as BRCA mutated. High or low glucocorticoid receptor expression was defined as expression above or below median of the GR/nuclear receptor subfamily 3 C1 (NR3C1) gene level. Overall survival was estimated by the Kaplan-Meier method and compared by Cox regression analysis. Results Combined germline DNA sequencing and tumor microarray expression data were available for 222 high-grade serous ovarian cancer cases. Among these, 47 had a deleterious germline and/or somatic mutation in BRCA1 or BRCA2. In multivariate analysis, high glucocorticoid receptor gene expression was associated with decreased overall survival among ovarian cancer patients, independently of BRCA mutation status. No correlation of GR/NR3C1 gene expression with BRCA mutation status or BRCA1 or BRCA2 mRNA level was observed. Conclusions Increased GR gene expression is associated with decreased overall survival in ovarian cancer patients, independently of BRCA mutation status. High-grade serous ovarian cancers with high GR expression and wild type BRCA have a particularly poor outcome.

Original languageEnglish (US)
Pages (from-to)357-364
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume29
Issue number2
DOIs
StatePublished - Feb 1 2019
Externally publishedYes

Fingerprint

Glucocorticoid Receptors
Ovarian Neoplasms
Mutation
Survival
Gene Expression
Cytoplasmic and Nuclear Receptors
Genome
Exome
Neoplasms
Atlases
DNA Sequence Analysis
Disease-Free Survival
Multivariate Analysis
Regression Analysis
Drug Therapy
Messenger RNA

Keywords

  • apoptosis
  • BRCA mutations
  • Epithelial ovarian cancer
  • glucocorticoid receptor
  • hormone receptor

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer. / Veneris, Jennifer Taylor; Huang, Lei; Churpek, Jane E.; Conzen, Suzanne D.; Fleming, Gini F.

In: International Journal of Gynecological Cancer, Vol. 29, No. 2, 01.02.2019, p. 357-364.

Research output: Contribution to journalArticle

@article{0247a7593aca469db6a920b2228f092f,
title = "Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer",
abstract = "Objective High glucocorticoid receptor (GR) protein expression is associated with decreased progression-free survival in ovarian cancer patients and decreased sensitivity to chemotherapy in preclinical models. Prior studies suggest wild type BRCA1 promotes GR activation. The objective of this study was to characterize the relationship of tumor GR gene expression to outcome in ovarian cancer, and to evaluate the relationship of GR expression with BRCA status. Methods Whole exome and whole genome sequencing, gene expression, and clinical data were obtained for high-grade serous ovarian cancers in The Cancer Genome Atlas. Cases with pathogenic somatic or germline BRCA1 or BRCA2 mutations were identified and classified as BRCA mutated. High or low glucocorticoid receptor expression was defined as expression above or below median of the GR/nuclear receptor subfamily 3 C1 (NR3C1) gene level. Overall survival was estimated by the Kaplan-Meier method and compared by Cox regression analysis. Results Combined germline DNA sequencing and tumor microarray expression data were available for 222 high-grade serous ovarian cancer cases. Among these, 47 had a deleterious germline and/or somatic mutation in BRCA1 or BRCA2. In multivariate analysis, high glucocorticoid receptor gene expression was associated with decreased overall survival among ovarian cancer patients, independently of BRCA mutation status. No correlation of GR/NR3C1 gene expression with BRCA mutation status or BRCA1 or BRCA2 mRNA level was observed. Conclusions Increased GR gene expression is associated with decreased overall survival in ovarian cancer patients, independently of BRCA mutation status. High-grade serous ovarian cancers with high GR expression and wild type BRCA have a particularly poor outcome.",
keywords = "apoptosis, BRCA mutations, Epithelial ovarian cancer, glucocorticoid receptor, hormone receptor",
author = "Veneris, {Jennifer Taylor} and Lei Huang and Churpek, {Jane E.} and Conzen, {Suzanne D.} and Fleming, {Gini F.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1136/ijgc-2018-000101",
language = "English (US)",
volume = "29",
pages = "357--364",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Wolters Kluwer Health",
number = "2",

}

TY - JOUR

T1 - Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer

AU - Veneris, Jennifer Taylor

AU - Huang, Lei

AU - Churpek, Jane E.

AU - Conzen, Suzanne D.

AU - Fleming, Gini F.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objective High glucocorticoid receptor (GR) protein expression is associated with decreased progression-free survival in ovarian cancer patients and decreased sensitivity to chemotherapy in preclinical models. Prior studies suggest wild type BRCA1 promotes GR activation. The objective of this study was to characterize the relationship of tumor GR gene expression to outcome in ovarian cancer, and to evaluate the relationship of GR expression with BRCA status. Methods Whole exome and whole genome sequencing, gene expression, and clinical data were obtained for high-grade serous ovarian cancers in The Cancer Genome Atlas. Cases with pathogenic somatic or germline BRCA1 or BRCA2 mutations were identified and classified as BRCA mutated. High or low glucocorticoid receptor expression was defined as expression above or below median of the GR/nuclear receptor subfamily 3 C1 (NR3C1) gene level. Overall survival was estimated by the Kaplan-Meier method and compared by Cox regression analysis. Results Combined germline DNA sequencing and tumor microarray expression data were available for 222 high-grade serous ovarian cancer cases. Among these, 47 had a deleterious germline and/or somatic mutation in BRCA1 or BRCA2. In multivariate analysis, high glucocorticoid receptor gene expression was associated with decreased overall survival among ovarian cancer patients, independently of BRCA mutation status. No correlation of GR/NR3C1 gene expression with BRCA mutation status or BRCA1 or BRCA2 mRNA level was observed. Conclusions Increased GR gene expression is associated with decreased overall survival in ovarian cancer patients, independently of BRCA mutation status. High-grade serous ovarian cancers with high GR expression and wild type BRCA have a particularly poor outcome.

AB - Objective High glucocorticoid receptor (GR) protein expression is associated with decreased progression-free survival in ovarian cancer patients and decreased sensitivity to chemotherapy in preclinical models. Prior studies suggest wild type BRCA1 promotes GR activation. The objective of this study was to characterize the relationship of tumor GR gene expression to outcome in ovarian cancer, and to evaluate the relationship of GR expression with BRCA status. Methods Whole exome and whole genome sequencing, gene expression, and clinical data were obtained for high-grade serous ovarian cancers in The Cancer Genome Atlas. Cases with pathogenic somatic or germline BRCA1 or BRCA2 mutations were identified and classified as BRCA mutated. High or low glucocorticoid receptor expression was defined as expression above or below median of the GR/nuclear receptor subfamily 3 C1 (NR3C1) gene level. Overall survival was estimated by the Kaplan-Meier method and compared by Cox regression analysis. Results Combined germline DNA sequencing and tumor microarray expression data were available for 222 high-grade serous ovarian cancer cases. Among these, 47 had a deleterious germline and/or somatic mutation in BRCA1 or BRCA2. In multivariate analysis, high glucocorticoid receptor gene expression was associated with decreased overall survival among ovarian cancer patients, independently of BRCA mutation status. No correlation of GR/NR3C1 gene expression with BRCA mutation status or BRCA1 or BRCA2 mRNA level was observed. Conclusions Increased GR gene expression is associated with decreased overall survival in ovarian cancer patients, independently of BRCA mutation status. High-grade serous ovarian cancers with high GR expression and wild type BRCA have a particularly poor outcome.

KW - apoptosis

KW - BRCA mutations

KW - Epithelial ovarian cancer

KW - glucocorticoid receptor

KW - hormone receptor

UR - http://www.scopus.com/inward/record.url?scp=85068309856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068309856&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2018-000101

DO - 10.1136/ijgc-2018-000101

M3 - Article

C2 - 30683758

AN - SCOPUS:85068309856

VL - 29

SP - 357

EP - 364

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -